Improving the accuracy of laboratory tests for HIV vaccines
Official title: External Quality Assurance Program Oversight Laboratory (EQAPOL)
Funded at Duke University · NIH-11191776 · Data updated 2026-11-12
This study is working to make sure that the lab tests used for HIV vaccines and treatments are accurate and reliable, so that patients can trust the new therapies being developed to be safe and effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2031 |
| Funding year | 2024 |
| Award (this year) | $3,890,109 |
| NIH project number | 75N93024D00003-0-759302400001-1 |
| Project ID | NIH-11191776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals involved in clinical trials for HIV vaccines or treatments.
✕Less likely to help
Patients who are not involved in HIV clinical trials or do not have HIV may not receive direct benefits from this research.
What this research studies
This research focuses on enhancing the reliability of laboratory tests used in clinical trials for HIV vaccines and treatments. It involves the External Quality Assurance Program Oversight Laboratory (EQAPOL), which monitors and ensures that laboratories conducting these tests produce accurate and reproducible results. By providing quality assurance and control, the program aims to support the development and approval of effective HIV vaccines and monoclonal antibodies. Patients can benefit from improved testing methods that ensure the safety and efficacy of new treatments.
Why it matters
Potential benefit: If successful, this research could lead to more reliable HIV vaccines and treatments, ultimately improving patient outcomes.
How similar studies have gone: Previous research has shown success in improving laboratory testing accuracy for other vaccine trials, indicating a promising approach.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Denny, Thomas — Duke University
- Study coordinator: Denny, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.